CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies. (2022)
Attributed to:
Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1182/blood.2021014840
PubMed Identifier: 35421218
Publication URI: http://europepmc.org/abstract/MED/35421218
Type: Journal Article/Review
Volume: 140
Parent Publication: Blood
Issue: 1
ISSN: 0006-4971